Go back

Go to
Igor Petricca

“We like to refer to ourselves as business-builders, creating a strategic vision and long-term value for companies that lasts far beyond ARCHIMED’s exit horizon. We are unafraid to make bold decisions, particularly concerning significant initiatives such as CAPEX investments, GMP certification, and greenfield projects.”



Sector: In Vitro Diagnostics & Consumer Health


Igor Petricca is a Partner at ARCHIMED.

Igor joined ARCHIMED in 2018, bringing in his rich experience of leading transactions in MedTech, In Vitro Diagnostics (IVD), Pharma Services and Consumer Health, both in Europe and North America. In 2022, he was appointed as a Partner.

Igor started his career at Mediobanca, an Italian investment bank, in the Principal Investing Department. He subsequently worked for seven years at Wise SGR, a Milan based Private Equity firm targeting mid-cap companies where he was contributed to several transactions including IPO’s, leverage buy outs and growth capital deals.

Igor currently holds board positions with an Italy-based manufacturer of aesthetic medicine, GPQ (WiQo), an Italy-based producer of IVD systems, DIESSE, a Canada-based CDMO and formulation development firm, Corealis Pharma Inc. and a US-based provider of consumable electrodes for neurodiagnostic and neurosurgery, Ad-Tech. Igor has led the take-private process of Bomi and numerous exit processes including Primo and Micromed.


Ad-Tech Medical Instrument
Bomi Group